Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich.
COVID-19
SARS-CoV-2
infection fatality ratio
population-based cohort study
seroprevalence
underreporting
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
30 03 2021
30 03 2021
Historique:
received:
18
02
2021
revised:
23
03
2021
accepted:
27
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
10
4
2021
Statut:
epublish
Résumé
Given the large number of mild or asymptomatic SARS-CoV-2 cases, only population-based studies can provide reliable estimates of the magnitude of the pandemic. We therefore aimed to assess the sero-prevalence of SARS-CoV-2 in the Munich general population after the first wave of the pandemic. For this purpose, we drew a representative sample of 2994 private households and invited household members 14 years and older to complete questionnaires and to provide blood samples. SARS-CoV-2 seropositivity was defined as Roche N pan-Ig ≥ 0.4218. We adjusted the prevalence for the sampling design, sensitivity, and specificity. We investigated risk factors for SARS-CoV-2 seropositivity and geospatial transmission patterns by generalized linear mixed models and permutation tests. Seropositivity for SARS-CoV-2-specific antibodies was 1.82% (95% confidence interval (CI) 1.28-2.37%) as compared to 0.46% PCR-positive cases officially registered in Munich. Loss of the sense of smell or taste was associated with seropositivity (odds ratio (OR) 47.4; 95% CI 7.2-307.0) and infections clustered within households. By this first population-based study on SARS-CoV-2 prevalence in a large German municipality not affected by a superspreading event, we could show that at least one in four cases in private households was reported and known to the health authorities. These results will help authorities to estimate the true burden of disease in the population and to take evidence-based decisions on public health measures.
Identifiants
pubmed: 33808249
pii: ijerph18073572
doi: 10.3390/ijerph18073572
pmc: PMC8038115
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bavarian State Ministry of Science and the Arts
ID : n/a
Organisme : University Hospital, LMU Munich
ID : n/a
Organisme : Helmholtz Centre Munich
ID : n/a
Organisme : University of Bonn
ID : n/a
Organisme : University of Bielefeld
ID : n/a
Organisme : German Ministry for Education and Research
ID : MoKoCo19, 01KI20271
Références
PLoS One. 2020 Aug 14;15(8):e0237833
pubmed: 32797108
Science. 2020 Nov 6;370(6517):691-697
pubmed: 33154136
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Med (N Y). 2021 Feb 12;2(2):149-163.e4
pubmed: 33163984
Am J Public Health. 2020 Jul;110(7):949-951
pubmed: 32324422
Lancet Infect Dis. 2021 Apr;21(4):e69-e70
pubmed: 32679085
Clin Chem Lab Med. 2020 Aug 27;58(12):2121-2130
pubmed: 32853163
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
Am J Epidemiol. 2021 Jan 4;190(1):109-115
pubmed: 32803245
BMC Public Health. 2020 Jun 30;20(1):1036
pubmed: 32605549
Trends Microbiol. 2016 Feb;24(2):123-133
pubmed: 26612500
Hum Brain Mapp. 2002 Jan;15(1):1-25
pubmed: 11747097
OTO Open. 2020 Sep 11;4(3):2473974X20957975
pubmed: 32964177
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Clin Exp Allergy. 2020 Dec;50(12):1313-1324
pubmed: 32975865
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
BMC Med Res Methodol. 2020 Jul 9;20(1):187
pubmed: 32646374
Science. 2020 Oct 23;370(6515):406-407
pubmed: 33093098
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347